SELECT MEDICAL HOLDINGS CORP Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Distributions from unconsolidated subsidiaries
Depreciation and amortization
Provision for expected credit losses
Equity in earnings of unconsolidated subsidiaries
Loss on extinguishment of debt
(Gain) loss on sale or disposal of assets
Stock compensation expense
Amortization of debt discount, premium and issuance costs
Deferred income taxes
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable
Other current assets
Other assets
Accounts payable
Accrued expenses
Government advances
Unearned government assistance
Net cash provided by operating activities
Investing activities
Business combinations, net of cash acquired
Purchases of property, equipment, and other assets
Investment in businesses
Proceeds from sales and exchanges of assets and sale of business
Net cash used in investing activities
Financing activities
Borrowings on revolving facilities
Payments on revolving facilities
Proceeds from term loans, net of issuance costs
Payments on term loans
Proceeds from 6.250% senior notes
Payment on 6.375% senior notes
Revolving facility debt issuance costs
Payment on senior notes, including call premium
Proceeds from senior notes, net of issuance costs
Borrowings of other debt
Principal payments on other debt
Dividends paid to common stockholders
Repurchase of common stock
Proceeds from exercise of stock options
Decrease in overdrafts
Proceeds from issuance of non-controlling interests
Distributions to and purchases of non-controlling interests
Purchase of membership interests of Concentra Group Holdings Parent
Proceeds from Concentra initial public offering
Cash transferred to Concentra at separation
Net cash used in financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental information:
Cash paid for interest, excluding amounts received of $82,818 and $68,069 under the interest rate cap contract for the years ended December 31, 2023 and 2024, respectively.
Cash paid for taxes
Non-cash investing and financing activities:
Liabilities for purchases of property and equipment

Comments